About Von Willebrand Disease — What is VWD
Humat-P for VWD — High-Quality VWF
Using Humate-P
The CSL Behring Commitment
Resources & Tools
Request More Information
Educational Program Links
AllAboutBleeding.com
Dosage Calculator
Customizable Patient Education Materials
VWF Densitometric Analysis
News & Events
Important Safety Information
Prescribing Information
Dosing Calculator
VWF Densitometric Analysis
Request More Information
For Patients

Dosage Calculator

This unique Humate-P® Dosage Calculator makes individual dosing fast, easy, and convenient. The calculator determines the correct Humate-P® loading dose (as measured in VWF:RCo units) needed to achieve the desired increase in circulating VWF, as defined in the product prescribing information. (For guidance on loading dose recommendations, please refer to Table 11 of the PI). All subsequent doses should be based on patient response and measured levels of VWF:RCo and FVIII.

These calculations are to be used only with Humate-P® and are applicable for the treatment of VWD and for the prevention of excessive bleeding during and after surgery in all VWD types.

Humate-P® VWD Dosage Calculator

Instructions: To determine the Humate-P® dose (as measured in VWF:RCo units) needed to achieve the target level of circulating VWF:

1) Enter the patient's body weight (BW) in kilograms (kg) OR pounds (lb)
2) Enter the patient's baseline level (BL) of VWF:RCo (measured as IU VWF:RCo/dL)
3) Enter the patient's target level (TL) of VWF:RCo (measured as IU VWF:RCo/dL)
4) Enter the patient's in vivo recovery (IVR). IVR is measured as rise in IU/dL per IU/kg administered. If unknown, please click on the link next to the IVR field and a value of 2 IU/dL will be used as the default per the dosage instructions in the product prescribing information.

BW   kg lb 
BL     
TL     
IVR   Click here
to use a default value of 2.0



A full chart is also available.


Printer friendly version


Important Safety Information®

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations, or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported in patients receiving Humate-P®, the most commonly reported are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.